Evolent Health Inc $ 13.06 -0.29 (-2.17%)
Volume:
1,290,576
Avg Vol (1m):
1,691,313
Market Cap $:
1.12 Bil
Enterprise Value $:
1.32 Bil
P/E (TTM):
0.00
P/B:
1.73
Financial Strength | 4/10 |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Cash-To-Debt | 0.33 | ||
| Equity-to-Asset | 0.51 | ||
| Debt-to-Equity | 0.46 | ||
| Debt-to-EBITDA | -0.67 | ||
| Piotroski F-Score | 4 | ||
| Altman Z-Score | 0.7 | ||
| Beneish M-Score | -3.29 | ||
| WACC vs ROIC | |||
Profitability Rank | 1/10 |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Operating Margin % | -7.81 | ||
| Net Margin % | -53.67 | ||
| ROE % | -54.33 | ||
| ROA % | -33.35 | ||
| ROC (Joel Greenblatt) % | -354.23 | ||
| 3-Year Revenue Growth Rate | 22.1 | ||
| 3-Year EBITDA Growth Rate | 14.5 | ||
| 3-Year EPS without NRI Growth Rate | -1.1 |
Valuation Rank |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| PB Ratio | 1.69 | ||
| PS Ratio | 1.16 | ||
| Price-to-Operating-Cash-Flow | 81.07 | ||
| EV-to-EBIT | -2.53 | ||
| EV-to-EBITDA | -2.87 | ||
| EV-to-Revenue | 1.38 | ||
| Current Ratio | 3.73 | ||
| Quick Ratio | 3.73 | ||
| Days Sales Outstanding | 41.63 | ||
| Days Payable | 42.78 |
Dividend & Buy Back |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -7.6 |
Valuation & Return |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Price-to-Tangible-Book | 116.45 | ||
| Price-to-Intrinsic-Value-Projected-FCF | 9.56 | ||
| Earnings Yield (Greenblatt) % | -39.67 |